Physician profile
Timothy Lenardo
NPI 1598873499
$8,553.22
in general payments reported to CMS, 2019-2025
21 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $538 · 2021: $201 · 2022: $1,476 · 2023: $1,575 · 2024: $1,824 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,909 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,909.27 |
| Education | $104.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,219.12 | 2019-2025 | |
| Amgen INC. | $1,946.97 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Novartis Pharmaceuticals Corporation | $1,457.50 | 2019-2025 | |
| Horizon Therapeutics Plc | $809.91 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $349.00 | 2022-2025 | Saphnelo |
| Pfizer INC. | $341.54 | 2019-2025 | |
| Janssen Biotech, INC. | $265.64 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $222.63 | 2019-2025 | Actemra |
| Celgene Corporation | $207.24 | 2019 | |
| Genzyme Corporation | $163.02 | 2024-2025 | |
| Ucb, INC. | $140.29 | 2022-2025 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $94.11 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $77.94 | 2020 | |
| Radius Health, INC. | $72.06 | 2019 | |
| Aurinia Pharma U.S., INC. | $36.53 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.60 | 2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.00 | 2023 | Cyltezo |
| Glaxosmithkline, LLC. | $23.58 | 2019 | |
| Sandoz INC. | $19.67 | 2024 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lenardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.